DoseMe Fuels Global Expansion with Appointment of Siegfried Bräuer to Director International Sales
31 Jan 2024
Executive Change
JUPITER, Fla.--(BUSINESS WIRE)--DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the appointment of Siegfried Bräuer to Director, International Sales. In this role, he will lead the expansion of DoseMe’s Model Informed Precision Dosing (MIPD) platform through channel partners and direct sales across multiple continents.
'I am confident that Sigi has the knowledge, skills, proven experience and passion to drive our vision forward and continue to make DoseMe the preferred choice for healthcare organizations.'
Siegfried Bräuer brings a wealth of experience in pharma with a long tenure at Merck. Additional roles at Swiss Alpinopharma, Amarin GmbH, Interim Management/Consulting and Canpharma, added to Siegfried ‘Sigi’ vast experience building teams across the emerging markets of the Eastern Europe, Middle East, and Africa region. Bräuer, an alumnus of Johannes Kepler University Linz and the MBA program at Emory University, joins DoseMe with more than 20 years of experience leading high-performance teams across pharmaceutical, commercialization and technology spanning multiple geographies including US, UK, Brazil and India.
"The healthcare industry is on a digital transformation journey and EMEA, MEA, Latin America and Asia are fast growing markets with the adoption of precision medicine on an upward trajectory," said Paul Edwards, CEO of DoseMe. "I am confident that Sigi has the knowledge, skills, proven experience and passion to drive our vision forward and continue to make DoseMe the preferred choice for healthcare organizations.”
In the past year, the company has expanded its distribution network with exclusive resellers across 29 countries. DoseMe continues to focus on product innovation and go-to-market expansion to build new drug models to broaden the MTDM platform. Under Bräuer’s leadership, diversify the channels and adding new partners will enable the company to offer a wide range of AI-powered systems for real-time patient care.
"DoseMe is at an inflection point as the advent of AI in precision dosing takes shape and is driving the increasing demand around the globe. I am excited to work with these exceptionally talented individuals to achieve our next phase of growth,” said Bräuer.
About DoseMe
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.